Prof. Dr. med. Denis Martin Schewe

Facts

Phone: +49-431-500-20140

E-Mail: denis.schewe@med.ovgu.de

Website:

www.kpae.ovgu.de

Affiliations: Pediatric Clinic / University Hospital Magdeburg

Address: Arnold-Heller-Str. 3, Bldg C, 24105 Kiel

Curriculum vitae

Education/Training

Since 2021	Head of the Department of Pediatrics, Otto von Guericke University Magdeburg
Since 2020	Project Leader, KULT-SH consortium for telemedicine in Pediatric Hematology/Oncology
Since 2015	Attending Physician, Department of Pediatrics I, Pediatric Hematology/Oncology, University Hospital Schleswig-Holstein, Kiel
2015	Board Certification in Pediatric Hematology/Oncology
2013-2015	Clinical Fellow, Department of Pediatrics I, Pediatric Hematology/Oncology, University Hospital Schleswig-Holstein, Kiel
2012	Board Certification in Pediatrics
2010	Board Certification in Emergency Medicine
2011-2012	Internship/Residency, Department of Pediatrics I, University Hospital Schleswig-Holstein, Kiel
2004-2011	Internship/Residency, Department of Pediatrics, LMU, Munich
2003	Harvard Medical School in Boston, MA, USA, stipend by the Harvard-Munich Alliance For Medical Education
1997-2003	Medical School in Munich, LMU

Research Experience/Academic Appointments

2020	APL-Professor in Pediatrics, Christian-Albrechts University Kiel
2016	”Habilitation”, Christian-Albrechts University Kiel
2011-2017	Max-Eder Junior Research Group Leader, stipend by the Deutsche Krebshilfe on dormancy and therapy resistance in pediatric ALL, Department of Pediatrics I, Kiel
2007-2008	Postdoctoral fellow, University at Albany and Mount Sinai Medical Center New York City (group of Julio Aguirre-Ghiso) on cancer dormancy, stipend by the Deutsche Krebshilfe
2004	MD thesis with “summa cum laude”
Fields of Interest	Translational research related to leukemia/niche interactions and novel immunotherapeutic strategies in lymphatic neoplasia, how to make immunotherapy more effective, digitalized medicine, telemedicine

Important Scientific Prizes/Functions

2019	Hensel-Prize, Hensel Foundation, 100.000€
Since 2018	Member of the BFM Biology and Diagnosis committee
2018	Young Leaders in Science stipend of the Schering-Stiftung, Berlin
2015	Erna-Brunner-Price 2015, Tübingen
2014	Translational Research Training in Hematology Award (TRTH 2014) of the European Hematology Association (EHA) and the American Society of Hematology (ASH)

Project-related publications

P3, P4, P6, P7, Z

Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL

Müller K, Vogiatzi F, Winterberg D, Rösner T, Lenk L, Bastian L, Gehlert CL, Autenrieb MP, Brüggemann M, Cario G, Schrappe M, Kulozik AE, Eckert C, Bergmann AK, Bornhauser B, Bourquin JP, Valerius T, Peipp M, Kellner C, Schewe DM

PubMed (PMID: 35452517)

Blood

2022

P4, P6, P7

Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab

Baumann, N, Arndt C, Petersen J, Lustig M, Rösner T, Klausz K, Kellner C, Bultmann M, Bastian L, Vogiatzi F, Leusen JHW, Burger R, Schewe DM, Peipp M, Valerius T

PubMed (PMID: 36052078)

Front Immunol

2022

P3, P6, P7, Z

Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B-cell Precursor Acute Lymphoblastic Leukemia

Lenk L, Winterberg D, Vogiatzi F, Laqua A, Spory A, Mayar A, Dietterle A, Münch G, Vokuhl C, Richter J, Polsen AG, Schüler T, Kahlert UD, Peipp M, Valerius T, Schrappe M, Cario G, Jumaa H, Hobeika E, Brüggemann M, Alsadeq A, Schewe DM

PubMed (PMID: 35935606)

Hemasphere

2022

P1, P4, P6

In vivo inducible reverse genetics in patients’ tumors to identify individual therapeutic targets

Carlet M*, Völse K*, Vergalli J, Becker M, Herold T, Arner A, Senft D, Jurinovic V, Liu WH, Gao Y, Dill V, Fehse B, Baldus CD, Bastian L, Lenk L, Schewe DM, Bagnoli JW, Vick B, Schmid JP, Wilhelm A, Marschalek R, Jost PJ, Miething C, Riecken K, Schmidt-Supprian M, Binder V, Jeremias I

*equally contributing first authors.

PubMed (PMID: 34580292)

Nat Commun.

2021

P1, P3, P6, Z

CD79a promotes CNS-infiltration and leukemia engraftment in pediatric B-cell precursor acute lymphoblastic leukemia

Lenk L, Carlet M, Vogiatzi F, Spory L, Winterberg D, Cousins A, Vossen-Gajcy M, Ibruli O, Vokuhl C, Cario G, El Ayoubi O, Kramer L, Ritgen M, Brüggemann M, Häsler R, Schrappe M, Fuhrmann S, Halsey C, Jeremias I, Hobeika E, Jumaa H, Alsadeq A, Schewe DM

PubMed (PMID: 33452446)

Commun Biol

2021

P1, P6, P7, Z

Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia

Vogiatzi F, Winterberg D, Lenk L, Buchmann S, Cario G, Schrappe M, Peipp M, Richter-Pechanska P, Kulozik AE, Lentes J, Bergmann AK, Valerius T, Frielitz FS, Kellner C, Schewe DM

PubMed (PMID: 31311816)

Blood

2019

P1, P6, Z

IKZF1 ^plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia

Stanulla M, Dagdan E, Zaliova M, Möricke A, Palmi C, Cazzaniga G, Eckert C, Te Kronnie G, Bourquin JP, Bornhauser B, Koehler R, Bartram CR, Ludwig WD, Bleckmann K, Groeneveld-Krentz S, Schewe D, Junk SV, Hinze L, Klein N, Kratz CP, Biondi A, Borkhardt A, Kulozik A, Muckenthaler MU, Basso G, Valsecchi MG, Izraeli S, Petersen BS, Franke A, Dörge P, Steinemann D, Haas OA, Panzer-Grümayer R, Cavé H, Houlston RS, Cario G, Schrappe M, Zimmermann M

TRANSCALL Consortium; International BFM Study Group.

PubMed (PMID: 29498923)

J Clin Oncol

2018

P1, P6, P7

An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts

Schewe DM, Alsadeq A, Sattler C, Lenk L, Vogiatzi F, Cario G, Vieth S, Valerius T, Rosskopf S, Meyersieck F, Alten J, Schrappe M, Gramatzki M, Peipp M, Kellner C

PubMed (PMID: 28698205)

Blood

2017

Prof. Dr. med. Denis Martin Schewe

Facts

Curriculum vitae

Education/Training

Research Experience/Academic Appointments

Important Scientific Prizes/Functions

Research groups

Project-related publications

Participating Institutes